RBS Investments, LLC v. ProAct, Inc.

CourtDistrict Court, E.D. Michigan
DecidedMay 9, 2025
Docket2:23-cv-12176
StatusUnknown

This text of RBS Investments, LLC v. ProAct, Inc. (RBS Investments, LLC v. ProAct, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. Michigan primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
RBS Investments, LLC v. ProAct, Inc., (E.D. Mich. 2025).

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF MICHIGAN SOUTHERN DIVISION

RBS INVESTMENTS, LLC,

Plaintiff, Case No. 23-cv-12176 v. Honorable Robert J. White PROACT, INC.,

Defendant.

ORDER GRANTING IN PART AND DENYING IN PART DEFENDANT’S MOTION FOR SUMMARY JUDGMENT

This case exemplifies the pitfalls parties may encounter when they do not write down the terms of their agreements. Plaintiff RBS Investments LLC, d/b/a Scout Rx Pharmacy Benefit Consultants (Scout) brought this action against Defendant ProAct, Inc. (ProAct) after ProAct terminated the parties’ business relationship. Scout asserted claims for: (1) breach of contract; (2) quantum meruit/unjust enrichment; (3) equitable estoppel; (4) promissory estoppel; (5) fraudulent misrepresentation; and (6) fraud in the inducement. (ECF No. 1-2, PageID.23–30). Scout also asked the Court to enter declaratory judgment and to issue an injunction against ProAct. (Id. at PageID.30–32). ProAct brought counterclaims for (1) breach of contract; (2) promissory estoppel; (3) unjust enrichment; and (4) fraud in the inducement. (ECF No. 10, PageID.164–70).

Before the Court is ProAct’s motion for summary judgment on all of Scout’s claims. (ECF No. 21). Neither party moved for summary judgment on ProAct’s counterclaims. At the heart of the parties’ present dispute is whether ProAct owes

Scout anything for its unilateral termination of the agreement, despite the absence of a written contract governing such terms. The parties fully briefed the motion, and the Court held oral argument. As explained below, the Court will grant in part and deny in part the motion.

I. Background Scout is a provider of pharmacy benefit consulting services. (ECF No. 1-2, PageID.21). Scout’s President, Richard Vanpraet, founded the company in 2019

with the purpose to lower drug costs for self-funded employer benefit groups. (ECF No. 21-3, PageID.453–54). The company achieves its purpose through its “Core Strategies” services. (ECF No. 1-2, PageID.21–22). The “Core Strategies” services consist of a series of programs generally defined as follows. Under the “specialty”

program, Scout advocated for plan members to receive Patient Assistance Plans (PAPs) from drug manufacturers. (ECF No. 21-3, PageID.464). If a member qualified for a PAP, the drug manufacturer would provide the drug for free or at a

substantial discount. (Id. at PageID.474–75). The “co-pay optimization” program involved the use of coupons to save the group money. (Id. at PageID.464). And the “international” program focused on procuring drugs from international suppliers.

(Id. at PageID.465). ProAct is a pharmacy benefits manager. (ECF No. 21-2, PageID.297–98). David Schryver serves as the company’s president and held this role during the

events at issue. (Id. at PageID.297). ProAct’s relationship with Scout formally began on January 1, 2020, when the parties entered into a service agreement for ProAct to provide Scout pharmacy benefit management (PBM) services. (Id.; ECF No. 21-5, PageID.758). As the pharmacy benefits manager for Scout, ProAct helped Scout

administer its program by managing tasks such as claims processing and planning bills and rebates. (ECF No. 21-2, PageID.297). The parties renewed the service agreement in January 2022. (ECF No. 21-6, PageID.794).

Sometime after the service agreement initially took effect, ProAct began contemplating an expansion of its own service offerings to include a service along the lines of what Scout offered, that is, lowering specialty drug costs for groups.

(ECF No. 21-2, PageID.298–99). Because of the parties’ pre-existing relationship, and because Scout had expertise in this area, ProAct believed a partnership between the two to establish ProAct’s own program would be “synergistic.” (Id. at

PageID.299). Discussions between ProAct and Scout about the potential program commenced between late 2020 and early 2021. (Id. at PageID.298). At an in-person meeting in April 2021, referred to as “the Summit,” representatives of ProAct and Scout discussed how such a program would work. (ECF No. 21-3, PageID.505–07).

Attendees included Vanpraet from Scout and ProAct’s Director of Account Management, David Mastrangelo, among others. (Id. at PageID.505).

Scout’s meeting minutes from the Summit outline what the parties discussed, namely, how the program would function. (ECF No. 21-7, PageID.831). The minutes explain comprehensively which party would be responsible for what and how the parties would be compensated. (Id.). Although Scout would not be the

exclusive service provider, it would be “the only internal white label option.” (Id. at PageID.832). “White label” refers to when a company provides services to another company and that company represents and sells the service as its own to the market.

(ECF No. 21-4, PageID.672). In practice, ProAct would sell its service to a group, but Scout would primarily provide the service. (Id. at 673). In addition, the parties agreed that groups joining the program would be

charged a fee equal to 25% of the drug cost savings realized; ProAct and Scout would split the fee according to the group size, with the range of revenue ProAct was entitled to varying between 25-35%. (ECF No. 21-7, PageID.832). The meeting

minutes did not mention what would happen in the event either party decided to terminate the arrangement. Scout indicated at the Summit that “if ProAct came onboard, ScoutRx will slow down our company sales to make sure we can accommodate the business that

[ProAct] steer[s] to [Scout].” (ECF No. 23-5, PageID.1236). In fact, Vanpraet informed ProAct’s representatives that it had “no problem turning away business from our internal sales perspective to ensure a long term growth strategy and

partnership with ProAct.” (Id.). Overall, the parties were enthusiastic and hopeful that the program would takeoff and succeed. (ECF No. 21-4, PageID.680–81). On May 3, 2021, Vanpraet reached out to Mastrangelo for his thoughts on a

Master Services Agreement (MSA) for the intended arrangement. (ECF No. 21-8, PageID.834). This was not the first mention of a potential MSA; the meeting minutes provided that “ScoutRx prefers an MSA will be developed to specifically

address this joint venture.” (ECF No. 21-7, PageID.832). Mastrangelo replied in agreement to Vanpraet’s email, and Vanpraet responded that he had tried “to change a couple of our contracts into something that would fit our arrangement” but it could not be done. (ECF No. 21-10, Page.844). Instead, the parties would have to build

out something new. (Id.). Mastrangelo forwarded Vanpraet’s emails to Schryver. (Id. at PageID.843). On May 7, Mastrangelo informed Vanpraet that the parties could pull plans for “duties and finances” from the meeting minutes but that he would need

more information. (ECF No. 21-12, PageID.910). Vanpraet replied he would work on it the following Monday. (Id.). Discussions about the MSA, however, tapered off in the lead-up to the program launch.

The parties labeled the program “ProActPlus.” (ECF No. 23-7, PageID.1240). In the lead up to its launch, Scout and ProAct worked together to draft a policy and

procedure statement outlining the parties’ respective responsibilities. (ECF No. 21- 13, PageID.916; ECF No. 21-2, PageID.303). The statement did not mention what would happen in the event either party terminated the business relationship. Instead, it described how ProAct would market ProActPlus and source new and existing

clients, compile a profile on prospective clients that it would send to Scout for Scout to project cost savings, and prepare a written proposal based on Scout’s projections. (ECF No. 21-13). If the client accepted the proposal, it would contract with ProAct

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
John MacDonald, Jr. v. Thomas M. Cooley Law School
724 F.3d 654 (Sixth Circuit, 2013)
Eerdmans v. Maki
573 N.W.2d 329 (Michigan Court of Appeals, 1998)
Hess v. Cannon Township
696 N.W.2d 742 (Michigan Court of Appeals, 2005)
Benson v. Department of Management & Budget
424 N.W.2d 40 (Michigan Court of Appeals, 1988)
Morris Pumps v. Centerline Piping, Inc.
729 N.W.2d 898 (Michigan Court of Appeals, 2007)
Kloian v. Domino's Pizza, LLC
733 N.W.2d 766 (Michigan Court of Appeals, 2007)
Custom Data Solutions, Inc v. Preferred Capital, Inc.
733 N.W.2d 102 (Michigan Court of Appeals, 2007)
Cascade Electric Co. v. Rice
245 N.W.2d 774 (Michigan Court of Appeals, 1976)
Thomas v. Leja
468 N.W.2d 58 (Michigan Court of Appeals, 1991)
Allstate Insurance v. Hayes
499 N.W.2d 743 (Michigan Supreme Court, 1993)
Novak v. Nationwide Mutual Insurance
599 N.W.2d 546 (Michigan Court of Appeals, 1999)
Kamalnath v. Mercy Memorial Hospital Corp.
487 N.W.2d 499 (Michigan Court of Appeals, 1992)
Hoye v. Westfield Insurance
487 N.W.2d 838 (Michigan Court of Appeals, 1992)
Stanton v. Dachille
463 N.W.2d 479 (Michigan Court of Appeals, 1990)
Huron Tool and Engineering Co. v. Precision Consulting Services, Inc.
532 N.W.2d 541 (Michigan Court of Appeals, 1995)
Belle Isle Grill Corp. v. City of Detroit
666 N.W.2d 271 (Michigan Court of Appeals, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
RBS Investments, LLC v. ProAct, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/rbs-investments-llc-v-proact-inc-mied-2025.